D. Khanna, K. Brown, P. Clements, R. Elashoff, D. Furst, J. Goldin, J. Seibold, R. Silver, D. Tashkin, A. Wells
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA. firstname.lastname@example.org
Free to view (click on article PDF icon to read the article)
Pulmonary disease is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Recent well-designed trials in SSc-associated interstitial lung disease (SSc-ILD) have provided important insights regarding outcome measures and trial design. Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review.
PMID: 20576216 [PubMed]
Received: 10/05/2010 - Accepted : 11/05/2010 - In Press: 24/06/2010 - Published: 24/06/2010